Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Status:
Completed
Trial end date:
2018-08-28
Target enrollment:
Participant gender:
Summary
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib
administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect
Cohorts) or with advanced solid tumors with FGFR genetic aberrations, including iCCA with
FGFR2 gene fusion (Part 2; Expanded Cohort, signal finding).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ArQule Basilea Pharmaceutica
Collaborator:
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)